Polypodium leucotomos targets multiple aspects of oral carcinogenesis and it is a potential antitumor phytotherapy against tongue cancer growth

• DOI: 10.3389/fphar.2022.1098374
• Publication Date: 2023-01-05T16:26:31Z
• Authors: Pammela A. Lacerda; Luan C. Oenning; Guilherme Cuoghi ...; Lucilene Lopes-Sa...; Natalícia de Jesu...; Bruno Augusto Lin...; Gabriela Teixeira; Rafael Vasconcelos; Gustavo Ferreira ...; Ivani Aparecida d...; Clóvis Antônio Lo...; Tuula Salo; Ricardo D. Coletta; Taize M. Augusto; Carine Ervolino d...; Nilva K. Cervigne
• Keywords: Phytotherapy

Introduction: Oral cancer refers to malignant tumors, of which 90% are squamous cell carcinomas (OSCCs). These malignancies exhibit rapid progression, poor prognosis, and often mutilating therapeutical approaches. The determination a prophylactic and/or therapeutic antitumor role the polyphenolic extract Polypodium leucotomos(PL) would be relevant in developing new tools for prevention treatment. Methods: We aimed determine effect PL by treating OSCC lines with metabolites evaluating its action during progression vivo . Results: treatment successfully impaired cycling proliferation, migration, invasion, enhanced apoptosis, modulated macrophage polarization associated tumoral immune-inflammatory response tongue (TSCC). significantly decreased expression MMP1 ( p < 0.01) MMP2 0.001), increased TIMP1 0.001) TIMP2 0.0001) these cells. mesenchymal-epithelial transition phenotype was promoted cells treated PL, through upregulation E-CAD reduction N-CAD 0.05). restrained inhibiting tumor volume growth decreasing number severe dysplasia lesions carcinomas. Ki-67 higher expressed tissues animals not PL( 0.05), notable Bcl2 0.05) Pcna proliferation-associated genes found dysplastic TSCCs PL-treated mice. Finally, N-cad(Cdh2), Vim, Twist were reduced PL. Conclusion: carcinogenic processes vitro inhibited also appears contribute modulation oral tumor-associated responses. Taken together, results suggest that plays an important carcinogenesis may potential phytotherapeutic target adjuvant